We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genetic Risk Factor for Premature Birth Found

By LabMedica International staff writers
Posted on 22 May 2014
Image: The iQ5 real-time polymerase chain reaction (PCR) detection system (Photo courtesy of Bio-Rad).
Image: The iQ5 real-time polymerase chain reaction (PCR) detection system (Photo courtesy of Bio-Rad).
A genetic risk factor for premature birth has been discovered and it is related to a gene that codes for a protein that the scientists have found helps the body’s immune cells recognize and fight group B streptococcal (GBS) bacteria.

These GBS bacteria also known as Streptococcus agalactiae, are found in the vagina or lower gastrointestinal tract of approximately 15% to 20% of healthy women, but may cause life-threatening infections, such as sepsis or meningitis in newborns, especially those born prematurely.

Scientists at University of California, San Diego (La Jolla, CA, USA) and their international collaborators, studied a pair of proteins that together helps balance the body’s immune response to pathogens, by directing some antimicrobial response without provoking excessive inflammation. They isolated neutrophils from whole blood from three to six different donors per genotype. Freshly isolated sterile human placentas obtained from caesarian section were used for preparation of amniotic epithelial membranes (AM).

The investigators performed gene expression analysis, cytokine secretion, and cell signaling studies. Real-time polymerase chain reaction (PCR) was performed on an iQ5 machine (Bio-Rad Laboratories; Hercules, CA, USA) and cytokines in culture supernatants were quantitated using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems; Minneapolis, MN, USA). Paraffin sections were deparaffinized, blocked for endogenous nonspecific sites, and stained with human anti-sialic acid-binding immunoglobulin-like lectin 5 (Siglec-5) and anti–Siglec-14 antibodies.

The team found that the protein Siglec-5 binds to the GBS pathogen and suppresses immune response to the microbe, while the other protein, Siglec-14, binds to the pathogen, and activates killing of the bacteria. These sialic acid-binding immunoglobulin-type lectins are cell surface receptors found typically on immune cells. They recognize and bind sialic acids, which are sugar molecules that densely coat cells. The gene for Siglec-14 is missing in some individuals, and the investigators have found that fetuses that lack the Siglec-14 protein are at higher risk of premature birth, likely due to an imbalanced immune response to the bacterial infection.

Victor Nizet, MD, professor of pediatrics and pharmacy and coauthor of the study said, “Pregnant women are universally screened for these bacteria during pregnancy and administered antibiotics intravenously during labor if they test positive to protect the infant from infection. Our study may explain why some women and their infants are at higher risk of acquiring severe GBS infections than others.” The study was published on May 5, 2014, in the Journal of Experimental Medicine.

Related Links:

University of California, San Diego
Bio-Rad Laboratories 
R&D Systems


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gastrointestinal Panel
Xpert® GI Panel
New
Gold Member
Platelet Function Analyzer
PL-12

Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more